Loading...
•
Dec 31, 2021
Vistagen Q3 2022 Earnings Report
Reported third quarter financial results and provided a corporate update.
Key Takeaways
VistaGen Therapeutics reported its third quarter results, reflecting progress in advancing novel therapies for mental health disorders. The company is anticipating Phase 3 data for studies in the PALISADE program for PH94B in social anxiety disorder later this year and expanding clinical programs to explore opportunities in additional mental health conditions.
Advanced late-stage PH94B clinical program, with progress towards topline data readouts for PALISADE-1 and PALISADE-2 Phase 3 trials in social anxiety disorder expected in mid-2022 and second half 2022, respectively.
Initiated PALISADE Long-term Safety Study and exploratory Phase 2A trial in adjustment disorder with anxiety (AjDA).
Made preparations for clinical development in additional anxiety indications.
Phase 1B exploratory study for AV-101 in combination with probenecid is underway.